Class Action Litigation Report® is a one-stop resource for tracking the most important class-action and multi-party litigation across the nation, and across all subjects with particular focus on...
Sept. 6 — CVS Pharmacy, Inc. must face a would-be class suit alleging it deceptively touted its vitamin E supplements as providing heart-health benefits ( Kaufman v. CVS Caremark Corp. , 1st Cir., No. 16-1199, 9/6/16 ).
Federal law doesn’t bar Ronda Kaufman’s claims under New York’s consumer law or her claims for unjust enrichment, the U.S. Court of Appeals for the First Circuit said Sept. 6, reviving the suit.
Kaufman alleged CVS misleads consumers because no scientifically valid studies show that the “heart health” statements are both true and not misleading.
A district court said the claims were barred because the label complies with regulations issued under the Federal Food, Drug and Cosmetic Act.
The FDCA precludes any state labeling requirement that’s not identical to federal ones.
But the appeals court said Kaufman plausibly alleged that CVS lacks substantiation for its heart health statements—meaning the claims wouldn’t be barred because the label doesn’t satisfy federal requirements.
CVS contended that Kaufman undercut her own argument by describing, in the complaint, seven studies providing the required substantiation.because the complaint described seven studies that it says provide the substantiation required under federal law.
But existence of the studies doesn’t render the claims implausible, the court said. Most weren’t designed to test whether vitamin E supports heart health.
Additionally, the studies may plausibly indicate that in the aggregate vitamin E, in the doses packaged by CVS, can even damage the heart.
Supplements that could harm health at the supplied or recommended dosage, bearing a label claiming the product supports health, may be misleading under federal law, the court said.
Goldman, Scarlato & Penny, P.C. represented the plaintiff.
A&G Law LLC represented CVS.
To contact the reporter on this story: Julie A. Steinberg at email@example.com
Copyright © 2016 The Bureau of National Affairs, Inc. All Rights Reserved.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)